Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Short term Debt: 2019-2025

Historic Short term Debt for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $6.5 million.

  • Beam Therapeutics' Short term Debt fell 22.62% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 22.62%. This contributed to the annual value of $8.4 million for FY2024, which is 22.22% down from last year.
  • Latest data reveals that Beam Therapeutics reported Short term Debt of $6.5 million as of Q3 2025, which was up 66.67% from $3.9 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Short term Debt high stood at $85.4 million for Q2 2021, and its period low was $3.9 million during Q2 2025.
  • For the 3-year period, Beam Therapeutics' Short term Debt averaged around $9.1 million, with its median value being $8.4 million (2024).
  • Its Short term Debt has fluctuated over the past 5 years, first soared by 596.19% in 2021, then slumped by 80.80% in 2022.
  • Beam Therapeutics' Short term Debt (Quarterly) stood at $42.2 million in 2021, then plummeted by 56.64% to $18.3 million in 2022, then tumbled by 40.98% to $10.8 million in 2023, then declined by 22.22% to $8.4 million in 2024, then declined by 22.62% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, $3.9 million for Q2 2025, and $5.2 million during Q1 2025.